Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of “Buy” by Analysts

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have earned an average rating of “Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $31.80.

Several analysts have recently issued reports on EYPT shares. Royal Bank Of Canada reduced their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. HC Wainwright upped their target price on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Chardan Capital increased their price target on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Finally, Citigroup increased their price target on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, March 9th.

Eyepoint Pharmaceuticals Price Performance

NASDAQ EYPT opened at $13.58 on Friday. Eyepoint Pharmaceuticals has a 1 year low of $7.94 and a 1 year high of $19.11. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -3.88 and a beta of 1.72. The company has a fifty day moving average price of $13.27 and a 200-day moving average price of $14.64.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.35 million. On average, research analysts anticipate that Eyepoint Pharmaceuticals will post -3.09 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Ramiro Ribeiro sold 2,437 shares of the stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $15.00, for a total transaction of $36,555.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.13% of the company’s stock.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV bought a new position in Eyepoint Pharmaceuticals during the first quarter valued at about $29,000. Mirae Asset Global Investments Co. Ltd. grew its position in Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after buying an additional 1,358 shares during the period. Russell Investments Group Ltd. bought a new position in Eyepoint Pharmaceuticals during the third quarter valued at about $76,000. Tower Research Capital LLC TRC grew its position in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after buying an additional 5,967 shares during the period. Finally, California State Teachers Retirement System grew its position in Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after buying an additional 794 shares during the period. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.